Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
IPOPEMA Securities's Sloan Ratio for the quarter that ended in Mar. 2026 was -15.17%.
As of Mar. 2026, IPOPEMA Securities has a Sloan Ratio of -15.17%, indicating there is a warning stage of accrual build up.
IPOPEMA Securities (WAR:IPE) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, IPOPEMA Securities has a Sloan Ratio of -15.17%, indicating there is a warning stage of accrual build up.
IPOPEMA Securities Sloan Ratio % Related Terms
IPOPEMA Securities Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for IPOPEMA Securities's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Capital Markets subindustry, IPOPEMA Securities's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IPOPEMA Securities Sloan Ratio % vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, IPOPEMA Securities's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where IPOPEMA Securities's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
IPOPEMA Securities's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
IPOPEMA Securities's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was 5.781 (Jun. 2025 ) + 1.907 (Sep. 2025 ) + 16.425 (Dec. 2025 ) + 5.489 (Mar. 2026 ) = zł29.6 Mil.
IPOPEMA Securities's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 94.548 (Jun. 2025 ) + 374.837 (Sep. 2025 ) + -430.301 (Dec. 2025 ) + 82.455 (Mar. 2026 ) = zł121.5 Mil.
IPOPEMA Securities's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -1.68 (Jun. 2025 ) + 3.628 (Sep. 2025 ) + 9.424 (Dec. 2025 ) + -7.445 (Mar. 2026 ) = zł3.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPOPEMA Securities (WAR:IPE) has a Sloan Ratio % of -15.17% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on IPOPEMA Securities and its competitors.
Is IPOPEMA Securities' Sloan Ratio % too high?
IPOPEMA Securities' current Sloan Ratio % is -15.17%. Overall, IPOPEMA Securities has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IPOPEMA Securities' Sloan Ratio % compare to MS and GS?
IPOPEMA Securities' Sloan Ratio % of -15.17% can be compared against companies in the Capital Markets industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Capital Markets company?
A good Sloan Ratio % depends on the Capital Markets industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on IPOPEMA Securities and its competitors. IPOPEMA Securities's current Sloan Ratio % is -15.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IPOPEMA Securities stock overvalued right now?
Based on GuruFocus' analysis, IPOPEMA Securities (WAR:IPE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł3.62, compared to a current price of zł7.40 — trading 104.4% above its estimated fair value. The current Sloan Ratio % is -15.17%. IPOPEMA Securities' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For IPOPEMA Securities (WAR:IPE), the current Sloan Ratio % is -15.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IPOPEMA Securities (WAR:IPE) Overvalued in 2026?
Based on GuruFocus' analysis, IPOPEMA Securities stock appears to be overvalued.
The current stock price of zł7.40 is trading 104.4% above its estimated GF Value™ of zł3.62.
GuruFocus considers IPOPEMA Securities to be Significantly Overvalued.
Key valuation signals for WAR:IPE:
Sloan Ratio %: -15.17%
GF Value™: zł3.62 vs. price of zł7.40 (104.4% above fair value)
No single metric tells the full story. See the WAR:IPE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IPOPEMA Securities SA is focused on brokerage activities, Business and management consulting, running an investment fund company and creating and managing investment funds, Management of portfolios of brokerage financial instruments, IT management activities, and IT consulting activities. It specializes in brokerage and company analysis services, investment banking services, as well as the distribution of investment products and investment advisory services addressed to a wide range of individual investors, the creation and management of closed-end and open-end investment funds and asset management, as well as business and IT consulting services.
57GF Score
Get the complete analysis for WAR:IPE
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:IPE has been successfully added to your 
